Product Pathways - Growth Factors/Cytokines
Human His6Interleukin-25/IL-17E (hHis6IL-25) #12337
Recombinant human His6IL-25 (hHis6IL-25) Tyr33-Gly177 (Accession #NP_073626) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant N-terminally His6-tagged hIL-25 has a calculated MW of 19,318. DTT-reduced protein migrates as a 26-32 kDa polypeptide. The nonreduced cystine-linked homodimer migrates as a 40-46 kDa protein. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant hHis6IL-25 was verified by amino acid sequencing.
>97% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hHis6IL-25. 30% migrates as monomer under nonreducing conditions. All lots are greater than 97% pure.
The bioactivity of recombinant hHis6IL-25 was determined by its ability to induce IL-5 production from TSLP-primed PBMC in the presence of IL-2. The ED50 of each lot is between 5-15 pg/ml.
The purity of recombinant hHis6IL-25 was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant hHis6IL-25 and staining overnight with Coomassie Blue.
IL-5 production from human PBMC costimulated with IL-2 and increasing concentrations of hHis6IL-25 was assessed. PBMC were treated with TSLP (100 ng/ml, 24 hr) and then costimulated with IL-2 (10 ng/ml) and increasing concentrations of hHis6IL-25. After 72 hr, cell supernatants were harvested and assayed for IL-5 by ELISA and the OD450 was determined.
Less than 0.01 ng endotoxin/1 μg hHis6IL-25.
With carrier: Lyophilized from a 0.22 μm filtered solution of hHis6IL-25 in 20 mM Tris, pH 7.2 containing 150 mM NaCl and 20 μg BSA per 1 μg hHis6IL-25. Carrier free: Lyophilized from a 0.22 μm filtered solution of hHis6IL-25 in 20 mM Tris, pH 7.2 containing 150 mM NaCl.
IL-25, also known as IL-17E, is a member of the IL-17 superfamily of cytokines. IL-25 is expressed in epithelial cells, CD4+ T cells, mast cells, and eosinophils (1). Many cell types are responsive to IL-25, including T cells, macrophages, and epithelial cells (1). The receptor for IL-25 consists of a heterodimer of IL-17RA and IL-17RB (1,2). IL-25 promotes Th2 type immune responses by induction of IL-5, IL-4, and IL-13 and may contribute to allergic inflammation and asthma (1-3). IL-25 has also been shown in research to promote Th9 cell activation and induces apoptosis in breast cancer cells (4,5).
- Iwakura, Y. et al. (2011) Immunity 34, 149-62.
- Rickel, E.A. et al. (2008) J Immunol 181, 4299-310.
- Petersen, B.C. et al. (2012) Nat Med 18, 751-8.
- Angkasekwinai, P. et al. (2010) Nat Immunol 11, 250-6.
- Furuta, S. et al. (2011) Sci Transl Med 3, 78ra31.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.